Answers are grounded in this paper and cite their sources.
Background Crohn's disease (CD) is an immune-mediated disorder marked by chronic gastrointestinal inflammation. Although its precise immune drivers and etiology remain unclear, intestinal dysbiosis has been implicated in its development. Butyrate-producing bacteria (BPB) are an important component of the gut microbiota and have multiple beneficial effects on the host. This study investigated the relative abundance of selected butyrate-producing bacterial groups and butyrate-synthesis pathway genes in stool from children with CD and age-comparable healthy controls. Methods Stool DNA from children with CD and age-comparable healthy controls was assayed by qPCR for Clostridium cluster IV, Clostridium cluster XIVa, and the butyryl-CoA:acetate CoA-transferase (BUT) and butyrate kinase (BUK) pathway genes. Target cycle thresholds were normalized to the universal 16S rRNA gene from the same extract ( Δ Ct). Groups were compared with Welch's t -test. Results In 19 children with CD and 15 age-comparable healthy controls, relative abundance of BUK-pathway genes did not differ between groups ( P = 0.6), whereas BUT-pathway gene abundance was significantly lower in patients with CD than in controls ( P = 0.013). Patients with CD also showed lower relative abundance of Clostridium cluster XIVa ( P < 0.0001) and cluster IV ( P = 0.004) Conclusion These findings indicate a lower relative abundance of BUT-pathway genes and of Clostridium clusters IV and XIVa in stool DNA from Saudi children with CD. The assays quantify gene copies in community DNA, not gene expression or fecal butyrate, and they support further evaluation of microbiota-targeted strategies rather than a direct therapeutic recommendation.
No takes yet. Share an insight, caveat, or question.
Assas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: